EWTX (Edgewise Therapeutics) Days Inventory : 0.00 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Edgewise Therapeutics's Average Total Inventories for the three months ended in Sep. 2024 was $0.00 Mil. Edgewise Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Edgewise Therapeutics's Days Inventory or its related term are showing as below:

EWTX's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 184.2
* Ranked among companies with meaningful Days Inventory only.

Edgewise Therapeutics's Days Inventory stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Edgewise Therapeutics Days Inventory Historical Data

The historical data trend for Edgewise Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edgewise Therapeutics Days Inventory Chart

Edgewise Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Edgewise Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Edgewise Therapeutics's Days Inventory

For the Biotechnology subindustry, Edgewise Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edgewise Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's Days Inventory falls into.

Edgewise Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Edgewise Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Edgewise Therapeutics's Days Inventory for the quarter that ended in Sep. 2024 is calculated as:

	Days Inventory (Q: Sep. 2024 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Jun. 2024 )	+	Total Inventories (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Edgewise Therapeutics (NAS:EWTX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Edgewise Therapeutics's Inventory Turnover for the three months ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Edgewise Therapeutics's Inventory to Revenue for the three months ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Edgewise Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Edgewise Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

1715 38th Street, Boulder, CO, USA, 80301

Website

https://www.edgewisetx.com

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Executives

John R Moore	officer: General Counsel	3200 WALNUT ST, BOULDER CO 80301
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Alan J Russell	director, officer: Chief Scientific Officer	3415 COLORADO AVE, BOULDER CO 80303
Behrad Derakhshan	officer: Chief Business Officer	3415 COLORADO AVE., BOULDER CO 80303
Joanne M. Donovan	officer: CMO	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Kevin Koch	director, officer: President and CEO	3200 WALNUT ST, BOULDER CO 80301
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan C Fox	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Marc Semigran	officer: Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017